Johnson & Johnson

Latest Headlines

Latest Headlines

J&J CEO Gorsky sees 'new horizon' in China, despite slowing growth

Johnson & Johnson has a Chinese strategy: long-term thinking. Despite an economic slowdown and regulatory crackdowns--and the example of other multinationals that have scaled back there--CEO Alex Gorsky figures it's worth it to ride out the storm.

J&J, Philips partner to develop hand-held blood test for neuropsychiatric disorders

Royal Philips and Janssen Pharmaceutical have partnered in a multiyear deal to create a hand-held, blood-based diagnostic for brain disorders. The test will be based on a product that Philips is already developing, the Minicare system. The financial details of the partnership were undisclosed.

Psoriasis data wars heat up at AAD with Novartis, Boehringer studies

Newcomers showed off at this year's American Academy of Dermatology meeting, with more than one touting Stelara-beating data--and prepping the market for an all-out psoriasis war.

Jury: Boy didn't prove J&J drug caused his breast growth

Johnson & Johnson won a split decision in Philadelphia court Friday, in the latest Risperdal lawsuit to go to trial. A jury decided that J&J did fail to warn doctors that the antipsychotic drug could cause breast development in boys, Reuters reports.

Seventure adds €25M to microbiome investment fund

Seventure Partners has added €25 million ($27 million) to its microbiome investment fund, bringing the total under management to €100 million. The move ups the financial firepower of the fund--which has invested in 5 companies since it started late in 2013--at a time when microbiome R&D is starting to take off.

J&J stays mum about cash, but biotech buyout is a landmark win for Index fund

J&J has snapped up XO1 for an undisclosed sum. It's a single-asset biotech offering a second-generation antithrombin to J&J's Xarelto. And it's the first to be sold off from a portfolio of 16 molecules that Index Ventures put together after assembling one of the original "asset-centric" funds.

Hep C meds cost-effective, but affordable? With new 46% discounts, maybe

When hepatitis C drugmakers started wooing payers with discounts, the cost cuts made the difference between an overwhelming burden and cost-effective spending. So say two new studies looking at the cost of treating the disease with a new generation of quite effective--but very expensive--treatments.

Imbruvica cocktail stalls CLL in new trial, raising hopes for bigger market

After agreeing to shell out a pretty penny for Imbruvica-maker Pharmacyclics earlier this month, AbbVie chief Richard Gonzalez assured investors that the drug had plenty of market growth ahead--and that much of that growth would come from moving into earlier lines of treatment in its approved indications, including CLL. Now, new Phase III results suggest the med is on the right track in that department.

Depomed picks up loan for second half of $1.05B Nucynta acquisition from J&J

After securing U.S. rights to Janssen's Nucynta franchise in mid-January this year, Depomed has now raised enough to pay for it in full. Nucynta fits nicely into Depomed's cadre of pain and neurological treatments, and the Newark, CA-based company's Acuform drug delivery tech already gives Nucynta an edge as an oral treatment.

GlaxoSmithKline and J&J back a $100M new Alzheimer's R&D project

GlaxoSmithKline, Johnson & Johnson and a group of industry titans are helping kick off a U.K. government-led fund designed to spotlight new approaches to dementia and Alzheimer's disease, kicking in $10 million to bankroll discovery work around the world.